BridgeBio Pharma Total Revenue

BridgeBio Pharma (BBIO) currently reports a total revenue of $680M as of June 2026. That compares with $240M in the prior-year period — up 187.5% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore BridgeBio Pharma's total revenue history and peer comparisons.

BridgeBio Pharma's total revenue increased from $240M to $680M — a 187.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Pharma's total revenue of $680M is lower than the Healthcare sector average of $110B. That is roughly 99.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

BridgeBio Pharma reported $680M in total revenue as of June 2026. That compares with $240M in the prior-year period — up 187.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $680M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.